Clinical trials: Oral Anticoagulants
Safety Issues, Anticoagulant Toxicity
Clinical Pharmacist Anticoagulant Stewardship
Initiative to improve direct anticoagulant utilization involving programmatic review by clinical pharmacists in collaboration with multidisciplinary team.
- Trial name
- NCT03527615
- Testing
- Clinical Pharmacist Medication Review
- Where
- Israel
- Volunteers
- 4,000 people
- Sponsor
- Hadassah Medical Organization
Atrial Fibrillation, Recurrent Venous Thromboembolism
Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD)
MACACOD is a clinical record in the usual clinical practice of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).
- Trial name
- MACACOD (NCT04042155)
- Testing
- dabigatran, rivaroxaban, apixaban or edoxaban
- Where
- Spain
- Volunteers
- 1,600 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Behcet Syndrome
Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome
In patients with Behçet's syndrome (BS), deep venous thrombosis (DVT) is thought to result from inflammation of the vessel wall rather than hyper coagulability.
- Trial name
- ACTOR (NCT06780462)
- Testing
- Corticosteroids + Rivaroxaban, Corticosteroids alone
- Where
- 17 sites in France
- Volunteers
- 134 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Thromboembolic Disease
Safety of Direct Oral Anticoagulant During Pregnancy
Pregnancy is a major risk factor of thromboembolic disease (2 to 10 increased risk of thromboembolic event for pregnant women). This risk is related to the physiological changes inducing venous stasis and hypercoagulability.
- Trial name
- SACOD (NCT06179823)
- Where
- France
- Volunteers
- 1,755,558 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Ischemic Stroke, TIA
Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events
Nondisabling cerebrovascular events represent the largest group of cerebrovascular disease with a high risk of recurrent stroke.
- Trial name
- ADANCE (NCT01924325)
- Testing
- Apixaban, Clopidogrel, Aspirin
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Xijing Hospital
Atrial Fibrillation
Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation
To describe the treatment perception from patients with non-valvular atrial fibrillation (NVAF) receiving Pradaxa® or VKA for stroke prevention by using the self-estimation questionnaire of PACT-Q during a 6-month study period.
- Trial name
- NCT03187197
- Testing
- Pradaxa®
- Where
- 24 sites in Taiwan
- Volunteers
- 1,315 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
The Effect Of Face-To-Face and Online-Education Provided To İndividuals With Atrial Fibrillation On Medication Adherence and Satisfaction
This randomized controlled study was conducted to investigate the effects of face-to-face Education and tele-education given to individuals with atrial fibrillation taking oral Anticoagulants on their medication compliance and…
- Trial name
- NCT06233721
- Testing
- Online education, Face-to-face education
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Cumhuriyet University
Atrial Fibrillation (AF)
Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual)
The purpose of the PAUSE-Virtual Study is to show that by changing pre-surgery visits with patients taking a blood thinner (direct oral anticoagulant (apixaban, dabigatran, edoxaban, rivaroxaban or warfarin) when the participant…
- Trial name
- PAUSEVirtual (NCT06844227)
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 1,780 people
- Sponsor
- McMaster University
Endstage Renal Disease, Direct Oral Anticoagulants (DOACs)
Effect of Apiban Therapy on AVF Maturation in ESRD Patients
End-stage renal disease (ESRD) is a growing global health burden, and the creation of a native arteriovenous fistula (AVF) is the gold standard for vascular access in patients requiring hemodialysis [1].
- Conditions
- Endstage Renal Disease, Direct Oral Anticoagulants (DOACs), Arteriovenous Fistula, Arteriovenous Fistula Occlusion
- Trial name
- NCT07559942
- Testing
- Apixaban
- Where
- Pakistan
- Volunteers
- 190 people
- Sponsor
- Combined military hospital lahore
Portal Vein Thrombosis, Anticoagulant Therapy
Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis
This study aims to explore the safety and efficacy of oral administration of a novel anticoagulant (rivaroxaban) in patients with cirrhosis accompanied by high-risk esophagogastric variceal bleeding and portal vein thrombosis…
- Conditions
- Portal Vein Thrombosis, Anticoagulant Therapy, Variceal Bleeding
- Trial name
- NCT07602062
- Testing
- Rivaroxaban
- Where
- China
- Volunteers
- 175 people
- Sponsor
- Shanghai Zhongshan Hospital